SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Both GLP-1RA and SGLT-2 inhibitors improve liver enzymes in patients with non-alcoholic fatty liver disease (NAFLD) and histological features of non-alcoholic steatohepatitis (NASH) and reduce liver fat content [100,101,102].